A plethora of biologic therapies are available for the treatment of allergic diseases, and many more are in the approval pipeline. These therapies have the potential to bring us closer to true precision medicine treatment of patients with allergic disease. Thus, it is important for allergist/immunologists to understand the mechanisms of action of these drugs, the potential pitfalls associated with their use, and the correct patients in which to use them. This course will highlight recent developments in biologic therapies in allergic disease, and delve into the lessons learned from other fields, such as rheumatology, where biologics have been employed for some time. Speakers will present the basic science, clinical utility, and historical perspective on the use of biologic therapies in immune-associated diseases.

LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

  • Discover the immunological basis of biologics therapies and the current and future immunotherapies in allergic disease
  • Identify the role of disease endotyping for the selection of optimal biologic therapies
  • Describe the evolution of the use of biologics in autoimmune disease, including potential pitfalls

 

Moderator Introduction
Leah  C. Kottyan, PhD
Cincinnati Children's Hospital Medical Center

<insert video>


From Bench to Bedside: How Biologics Come Alive
Bruce  S. Bochner, MD FAAAAI

Northwestern University



Biologics in Autoimmune Diseases: Lessons Learned
Eveline  Y. Wu, MD, MSCR
University of North Carolina at Chapel Hill

<insert video>


Precision Therapy for Treatment of Allergic Disease
Antonella Cianferoni, MD PhD FAAAAI
Children

<insert video>


Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency Diseases
Jennifer Leiding, MD FAAAAI
University of South Florida

<insert video>


Personalized Genetic Approaches for Screening and Endotyping of Patients
Ivan Chinn, MD
Baylor College of Medicine

<insert video>


 

Please take a moment to click the link below and give us your feedback on this session:  

>>Evaluation